Safety and effectiveness of GMCN-508A for transfusion-dependent alpha thalassemia
Part of Blood & lymphatic clinical trials.
This Phase 1 study tests a new medicine (GMCN-508A) to see how safe it is and whether it can help people with transfusion-dependent alpha thalassemia. Participants are also expected to follow a treatment plan that includes stem cell transplantation preparation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal guardian) can understand the study and sign consent
- Age 5 to 35, any gender
- You have transfusion-dependent alpha thalassemia (regular red-blood-cell transfusions in the last 24 weeks)
- You have a good activity/health score (Karnofsky or Lansky at least 70)
- Your doctor plans you for autologous stem cell transplant and conditioning
- If you could become pregnant, you agree to effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called an anti-CD25 antibody to see if it can prevent graft-versus-host disease (a condition where donor cells attack the body) in people with transfusion-dependent thalassemia who are getting a stem cell transplant from a partially matched or unrelated donor.
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
This early-phase trial studies HGI-002 to see if it’s safe and can help people with severe alpha thalassemia who need frequent blood transfusions. It also requires planning for a special treatment approach that includes busulfan pre-treatment and stem cell transplantation.
This study tests an experimental drug called YOLT-204 to see if it is safe and can help people with transfusion-dependent beta-thalassemia need fewer blood transfusions. It is for adults aged 18 to 35 who have a specific type of thalassemia and are otherwise healthy enough for the trial.
This trial tests a new treatment called CS-101 for people with beta-thalassemia who need regular blood transfusions. It aims to see if CS-101 can help reduce transfusion needs.
This study tests a special system (Hemanext One) that stores red blood cells with less oxygen, to see if it helps people with thalassemia who need regular transfusions. It may reduce side effects or improve how well the transfusions work.
Hear when a new Transfusion Dependent Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.